News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Pharmaceutical Industries Limited (TEVA) Asks Supreme Court To Review Copaxone Ruling



1/23/2014 11:40:11 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Teva Pharmaceuticals has filed a petition with the U.S. Supreme Court asking for a review of a lower court’s ruling that invalidated key patents for the company’s multiple sclerosis drug Copaxone. A Teva spokeswoman confirmed the filing, but said the company would have no additional comment on the matter. Copaxone, which generated about $3.8 billion in sales for Teva (NYSE: TEVA) last year, is scheduled to lose patent protect in May.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES